CRISPR-mediated TCR replacement generates superior anticancer transgenic t cells

Blood

Volumn 131, Issue 3, 2018, Pages 311-322

  Legut, Mateusz ^a   Dolton, Garry ^a   Mian, Afsar Ali ^a   Ottmann, Oliver G ^a   Sewell, Andrew K ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

T LYMPHOCYTE RECEPTOR; ANTINEOPLASTIC AGENT; LYMPHOCYTE ANTIGEN RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOPTIVE TRANSFER; ARTICLE; BLAST CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ENGINEERING; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; CONTROLLED STUDY; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TRANSGENICS; CRISPR CAS SYSTEM; GENE KNOCKOUT; GENETICS; HEK293 CELL LINE; HEMATOLOGIC DISEASE; IMMUNOLOGY; METABOLISM; PATHOLOGY; REPRODUCIBILITY; T LYMPHOCYTE RECEPTOR GENE; TRANSGENE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CRISPR-ASSOCIATED PROTEIN 9; CRISPR-CAS SYSTEMS; GENE KNOCKOUT TECHNIQUES; GENES, T-CELL RECEPTOR; HEK293 CELLS; HEMATOLOGIC NEOPLASMS; HUMANS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; REPRODUCIBILITY OF RESULTS; T-LYMPHOCYTES; TRANSGENES;

EID: 85040832868     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2017-05-787598     Document Type: Article

References (75)

1. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314(5796):126-129.
2. Johnson LA, Morgan RA, Dudley ME, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009;114(3):535-546.
3. Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010;116(20): 4099-4102.
4. Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29(7): 917-924.
5. Robbins PF, Kassim SH, Tran TLN, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res. 2015;21(5): 1019-1027.
6. Morris EC, Stauss HJ. Optimizing T-cell receptor gene therapy for hematologic malignancies. Blood. 2016;127(26):3305-3311.
7. Kochenderfer JN, Rosenberg SA. Treating B-cellcancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol. 2013;10(5):267-276.
8. Attaf M, Legut M, Cole DK, Sewell AK. The T cell antigen receptor: the Swiss army knife of the immune system. Clin Exp Immunol. 2015; 181(1):1-18.
9. Willcox CR, Pitard V, Netzer S, et al. Cyto-megalovirus and tumor stress surveillance by binding of a human gd T cell antigen receptor to endothelial protein C receptor. Nat Immunol. 2012;13(9):872-879.
10. Arnett HA, Viney JL. Immune modulation by butyrophilins. Nat Rev Immunol. 2014;14(8): 559-569.
11. Legut M, Cole DK, Sewell AK. The promise of gd T cells and the gd T cell receptor for cancer immunotherapy. Cell Mol Immunol. 2015; 12(6):656-668.
12. Ahmadi M, King JW, Xue S-A, et al. CD3 limits the efficacy of TCR gene therapy in vivo. Blood. 2011;118(13):3528-3537.
13. van Loenen MM, de Boer R, Amir AL, et al. Mixed T cell receptor dimers harbor potentially harmful neoreactivity. Proc Natl Acad Sci USA. 2010;107(24):10972-10977.
14. Li Y, Moysey R, Molloy PE, et al. Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat Biotechnol. 2005;23(3):349-354.
15. Govers C, Sebestyén Z, Coccoris M, Willemsen RA, Debets R. T cell receptor gene therapy: strategies for optimizing transgenic TCR pairing. Trends Mol Med. 2010;16(2): 77-87.
16. Rapoport AP, Stadtmauer EA, Binder-Scholl GK, et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med. 2015; 21(8):914-921.
17. Cameron BJ, Gerry AB, Dukes J, et al. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med. 2013;5(197):197ra103.
18. Raman MC, Rizkallah PJ, Simmons R, et al. Direct molecular mimicry enables off-target cardiovascular toxicity by an enhanced affinity TCR designed for cancer immunotherapy. Sci Rep. 2016;6:18851.
19. Nijmeijer BA, Szuhai K, Goselink HM, et al. Long-term culture of primary human lymphoblastic leukemia cells in the absence of serum or hematopoietic growth factors. Exp Hematol. 2009;37(3):376-385.
20. Lang F, Wojcik B, Bothur S, et al. Plastic CD34 and CD38 expression in adult B-cell precursor acute lymphoblastic leukemia explains ambiguity of leukemia-initiating stem cell populations. Leukemia. 2017;31(3):731-734.
21. Amoli MM, Carthy D, Platt H, Ollier WE. EBV immortalization of human B lymphocytes separated from small volumes of cryo-preserved whole blood. Int J Epidemiol. 2008; 37(suppl 1):i41-i45.
22. Evans M, Borysiewicz LK, Evans AS, et al. Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6. J Immunol. 2001;167(9):5420-5428.
23. Cole DK, Edwards ES, Wynn KK, et al. Modification of MHC anchor residues generates heteroclitic peptides that alter TCR binding and T cell recognition. J Immunol. 2010; 185(4):2600-2610.
24. Nunes CT, Miners KL, Dolton G, et al. A novel tumor antigen derived from enhanced degradation of bax protein in human cancers. Cancer Res. 2011;71(16):5435-5444.
25. Cole DK, Yuan F, Rizkallah PJ, et al. Germ line-governed recognition of a cancer epitope by an immunodominant human T-cell receptor. J Biol Chem. 2009;284(40):27281-27289.
26. Madura F, Rizkallah PJ, Holland CJ, et al. Structural basis for ineffective T-cell responses to MHC anchor residue-improved “heteroclitic” peptides. Eur J Immunol. 2015;45(2): 584-591.
27. Kim JH, Lee S-R, Li L-H, et al. High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebra-fish and mice. PLoS One. 2011;6(4):e18556.
28. Sanjana NE, Shalem O, Zhang F. Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods. 2014;11(8):783-784.
29. Tungatt K, Bianchi V, Crowther MD, et al. Antibody stabilization of peptide-MHC mul-timers reveals functional T cells bearing extremely low-affinity TCRs. J Immunol. 2015; 194(1):463-474.
30. Roederer M, Nozzi JL, Nason MC. SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A. 2011;79(2):167-174.
31. Bilal MY, Vacaflores A, Houtman JC. Optimization of methods for the genetic modification of human T cells. Immunol Cell Biol. 2015; 93(10):896-908.
32. Schodin BA, Tsomides TJ, Kranz DM. Correlation between the number of T cell receptors required for T cell activation and TCR-ligand affinity. Immunity. 1996;5(2):137-146.
33. Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999; 401(6754):708-712.
34. Fuertes Marraco SA, Neubert NJ, Verdeil G, Speiser DE. Inhibitory receptors beyond T cell exhaustion. Front Immunol. 2015;6:310.
35. Tan MP, Gerry AB, Brewer JE, et al. T cell receptor binding affinity governs the functional profile of cancer-specific CD81 T cells. Clin Exp Immunol. 2015;180(2):255-270.
36. Tan MP, Dolton GM, Gerry AB, et al. Human leucocyte antigen class I-redirected anti-tumour CD4(1) T cells require a higher T cell receptor binding affinity for optimal activity than CD8(1) T cells. Clin Exp Immunol. 2017; 187(1):124-137.
37. Price DA, Sewell AK, Dong T, et al. Antigen-specific release of beta-chemokines by anti-HIV-1 cytotoxic T lymphocytes. Curr Biol. 1998;8(6):355-358.
38. Laugel B, Price DA, Milicic A, Sewell AK. CD8 exerts differential effects on the deployment of cytotoxic T lymphocyte effector functions. Eur J Immunol. 2007;37(4):905-913.
39. Ekeruche-Makinde J, Miles JJ, van den Berg HA, et al. Peptide length determines the outcome of TCR/peptide-MHCI engagement. Blood. 2013;121(7):1112-1123.
40. Wooldridge L, Ekeruche-Makinde J, van den Berg HA, et al. A single autoimmune T cell receptor recognizes more than a million different peptides. J Biol Chem. 2012;287(2): 1168-1177.
41. Cole DK, Bulek AM, Dolton G, et al. Hotspot autoimmune T cell receptor binding underlies pathogen and insulin peptide cross-reactivity. J Clin Invest. 2016;126(6):2191-2204.
42. Harly C, Guillaume Y, Nedellec S, et al. Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human gd T-cell subset. Blood. 2012;120(11): 2269-2279.
43. Sandstrom A, Peigné C-M, Léger A, et al. The intracellular B30.2 domain of butyrophilin 3A1 binds phosphoantigens to mediate activation of human Vg9Vd2 T cells. Immunity. 2014; 40(4):490-500.
44. Vavassori S, Kumar A, Wan GS, et al. Butyrophilin 3A1 binds phosphorylated antigens and stimulates human gd T cells. Nat Immunol. 2013;14(9):908-916.
45. Gober HJ, Kistowska M, Angman L, Jenö P, Mori L, De Libero G. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med. 2003;197(2):163-168.
46. Airoldi I, Bertaina A, Prigione I, et al. gd T-cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR-ab1/CD191 lymphocytes. Blood. 2015; 125(15):2349-2358.
47. Kershaw MH, Westwood JA, Slaney CY, Darcy PK. Clinical application of genetically modified T cells in cancer therapy. Clin Transl Immunology. 2014;3(5):e16.
48. Provasi E, Genovese P, Lombardo A, et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat Med. 2012;18(5):807-815.
49. Torikai H, Reik A, Liu PQ, et al. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR [published correction appears in Blood. 2015;126(22):2527]. Blood. 2012;119(24):5697-5705.
50. Berdien B, Mock U, Atanackovic D, Fehse B. TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer. Gene Ther. 2014;21(6):539-548.
51. Poirot L, Philip B, Schiffer-Mannioui C, et al. Multiplex genome-edited T-cell manufacturing platform for “off-the-shelf” adoptive T-cell immunotherapies. Cancer Res. 2015;75(18): 3853-3864.
52. Ren J, Liu X, Fang C, Jiang S, June CH, Zhao Y. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin Cancer Res. 2017;23(9):2255-2266.
53. Qasim W, Zhan H, Samarasinghe S, et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells [published correction appears in Sci Transl Med. 2017;9(377)]. Sci Transl Med. 2017;9(374).
54. Osborn MJ, Webber BR, Knipping F, et al. Evaluation of TCR gene editing achieved by TALENs, CRISPR/Cas9, and megaTAL nucleases. Mol Ther. 2016;24(3):570-581.
55. Eyquem J, Mansilla-Soto J, Giavridis T, et al Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature. 2017;543(7643):113-117.
56. Ding Z-C, Huang L, Blazar BR, et al. Poly-functional CD41 T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy. Blood. 2012;120(11): 2229-2239.
57. Sen DR, Kaminski J, Barnitz RA, et al. The epigenetic landscape of T cell exhaustion. Science. 2016;354(6316):1165-1169.
58. Hanson WM, Chen Z, Jackson LK, et al. Reversible oligonucleotide chain blocking enables bead capture and amplification of T-cell receptor a and b chain mRNAs. J Am Chem Soc. 2016;138(35):11073-11076.
59. Godder KT, Henslee-Downey PJ, Mehta J, et al. Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant. 2007;39(12): 751-757.
60. Wilhelm M, Kunzmann V, Eckstein S, et al. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood. 2003;102(1):200-206.
61. Abe Y, Muto M, Nieda M, et al. Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma. Exp Hematol. 2009;37(8):956-968.
62. Kunzmann V, Smetak M, Kimmel B, et al. Tumor-promoting versus tumor-antagonizing roles of gd T cells in cancer immunotherapy: results from a prospective phase I/II trial. J Immunother. 2012;35(2):205-213.
63. Welton JL, Morgan MP, Martí S, et al. Monocytes and gd T cells control the acute-phase response to intravenous zoledronate: insights from a phase IV safety trial. J Bone Miner Res. 2013;28(3):464-471.
64. Johnson LA, June CH. Driving gene-engineered T cell immunotherapy of cancer. Cell Res. 2017;27(1):38-58.
65. Sicard H, Ingoure S, Luciani B, et al. In vivo immunomanipulation of V gamma 9V delta 2 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model. J Immunol. 2005;175(8):5471-5480.
66. Oberg HH, Kellner C, Peipp M, et al. Monitoring circulating gd T cells in cancer patients to optimize gd T cell-based immunotherapy. Front Immunol. 2014;5:643.
67. Klebanoff CA, Gattinoni L, Restifo NP. Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy? J Immunother. 2012;35(9):651-660.
68. Reissfelder C, Stamova S, Gossmann C, et al. Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis. J Clin Invest. 2015;125(2):739-751.
69. Street SE, Trapani JA, MacGregor D, Smyth MJ. Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med. 2002;196(1):129-134.
70. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol. 2004;75(2):163-189.
71. Dieli F, Vermijlen D, Fulfaro F, et al. Targeting human gammadelta T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res. 2007;67(15):7450-7457.
72. Meraviglia S, Eberl M, Vermijlen D, et al. In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin Exp Immunol. 2010;161(2):290-297.
73. Nicol AJ, Tokuyama H, Mattarollo SR, et al. Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours. Br J Cancer. 2011;105(6): 778-786.
74. Wilhelm M, Smetak M, Schaefer-Eckart K, et al. Successful adoptive transfer and in vivo expansion of haploidentical gd T cells. J Transl Med. 2014;12(1):45.
75. 10.1182/blood-2017-05-787598